Artiva Biotherapeutics, Inc., an oncology company that is developing and commercializing allogeneic natural killer (NK) cell therapies, announced today the launch of the company with the close of a $78 million Series A financing.

The financing was co-led by 5AM Ventures, venBio Partners, and RA Capital Management. Additional investors include Medivate Partners, seed investors and strategic partners Green Cross LabCell Corporation and Green Cross Holdings Corporation.

Artiva will use the proceeds of this financing to develop off-the-shelf universal NK cells for use in combination with monoclonal antibody therapy and tumor targeting CAR-NK cell therapies, according to a news release. 

"We have seen tremendous breakthroughs in redirecting immune cells against cancer, but patient access to these therapies has been limited by safety, scale, manufacturing, logistics, and cost issues," said Tom Farrell, President and CEO of Artiva. "Our goal at Artiva is to do more, leveraging GC LabCell's foundational work on true off-the-shelf NK cells into a pipeline of product candidates that are accessible to any cancer patient who may benefit."

Artiva is advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, including CAR-NK cell therapies, that leverage the company's unique manufacturing and engineering capabilities. Artiva is headquartered in San Diego.